EmboCept
Overview:
EmboCept® S DSM 50 µm is certified for chemoembolization of inoperable liver and lung tumours (DSM-TACE).
Documents:
EmboCept Case Study – Mets From Ovarian Cancer
EmboCept Case Study – Transpulmonary Chemoembolization of NSCLC
CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation
| Material | Amilomer (DSM* 35/50) |
| Half-Life | 30-40 Minutes |
| Average Size of Microspheres | 50 µm ± 7 ųm |
| Size Distribution of Microspheres | Min 95% 20-90 µm // Max 4.0% > 90 µm // Max 2.5% > 20 µm |
| Indication | Transarterial chemoembolization (TACE) of inoperable liver and lung tumours. |
| Dosage | 2.5 – 7.5 ml (150 – 450 mg), depending on tumour size and vascularization, arterial blood flow and arteriovenous shunt volume. Maximum dose of 15 ml (900 mg) possible in individual cases. |
| Mechanism of Action | Reduction of blood flow causes short term ischemia in addition to a local concentration increase of the simultaneously applied cytostatic agent. |
| Package Size | 450 mg Amilomer in 7.5 ml saline solution. |
